Fig. 1: Lower MTAP expression predicts a worse prognosis. The target of the inhibitor is ubiquitously expressed in glioma and there is a co-growth correlation of expression. | Cell Death Discovery

Fig. 1: Lower MTAP expression predicts a worse prognosis. The target of the inhibitor is ubiquitously expressed in glioma and there is a co-growth correlation of expression.

From: Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models

Fig. 1

A Difference in RNA expression of MTAP, PRMT5, and MAT2A genes between tumor tissues and normal tissues in TCGA 2016 glioma database. B Difference in DAB staining, mean of MTAP, PRMT5, and MAT2A in tissue microarray (n = 61). C Difference in overall survival time between the 2 groups with high and low MTAP expression. D Differences in overall survival among the 4 groups. Each group is categorized by high and low expression of PRMT5 and MAT2A. E Correlation scatter plot of MTAP, PRMT5, and MAT2A genes in TCGA 2016 glioma database. F Correlation scatter plot of DAB staining, mean values of MTAP, PRMT5, and MAT2A genes in tissue microarray (n = 61). G Western blotting of MTAP, PRMT5, MAT2A, and SDMA in different glioma cell lines and the statistical analysis bar chart (n = 3). H–J Immunofluorescence to determine the expression of MTAP, PRMT5, and MAT2A in 3 glioma cell lines and the statistical analysis bar chart (scale bar = 100 μm) (n = 3).

Back to article page